Pages that link to "Q28567691"

The following pages link to Erythropoietin induction by electroconvulsive seizure, gene regulation, and antidepressant-like behavioral effects (Q28567691):

Displaying 30 items.

• Neuroplasticity and the next wave of antidepressant strategies (Q21129480) (← links)
• Erythropoietin Pathway: A Potential Target for the Treatment of Depression (Q26750850) (← links)
• Erythropoietin: new directions for the nervous system (Q26828425) (← links)
• Unexpected benefits of intermittent hypoxia: enhanced respiratory and nonrespiratory motor function (Q27000674) (← links)
• Erythropoietin (Q28563042) (← links)
• Diabetes mellitus: channeling care through cellular discovery (Q33749358) (← links)
• Intermittent hypoxia promotes hippocampal neurogenesis and produces antidepressant-like effects in adult rats. (Q34139529) (← links)
• Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder (Q34258204) (← links)
• Novel avenues of drug discovery and biomarkers for diabetes mellitus (Q34552287) (← links)
• Toward an anti-inflammatory strategy for depression (Q34852990) (← links)
• Antidepressant-like effects of erythropoietin: a focus on behavioural and hippocampal processes (Q34982719) (← links)
• The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study (Q35642010) (← links)
• Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses (Q36832872) (← links)
• Depression and antidepressants: molecular and cellular aspects. (Q37517285) (← links)
• Vascular growth factors in neuropsychiatry (Q37633688) (← links)
• Erythropoietin for infants with hypoxic-ischemic encephalopathy (Q37678885) (← links)
• Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial (Q37705741) (← links)
• VGF: An inducible gene product, precursor of a diverse array of neuro-endocrine peptides and tissue-specific disease biomarkers (Q37881441) (← links)
• Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression (Q37938732) (← links)
• The Use of ECT and MST in treating depression (Q37971397) (← links)
• Cytokines as biomarkers in depressive disorder: current standing and prospects. (Q38154918) (← links)
• Erythropoietin as a new therapeutic opportunity in brain inflammation and neurodegenerative diseases. (Q38269081) (← links)
• Transfection of primary brain capillary endothelial cells for protein synthesis and secretion of recombinant erythropoietin: a strategy to enable protein delivery to the brain (Q40292313) (← links)
• Neurotrophic paths in the treatment of depression (Q42575451) (← links)
• Erythropoietin prevents the effect of chronic restraint stress on the number of hippocampal CA3c dendritic terminals-relation to expression of genes involved in synaptic plasticity, angiogenesis, inflammation, and oxidative stress in male rats. (Q47813569) (← links)
• Electroconvulsive seizures stimulate the vegf pathway via mTORC1 (Q48786438) (← links)
• Carbamoylated erythropoietin modulates cognitive outcomes of social defeat and differentially regulates gene expression in the dorsal and ventral hippocampus. (Q55477135) (← links)
• GSK3β: a plausible mechanism of cognitive and hippocampal changes induced by erythropoietin treatment in mood disorders? (Q57477426) (← links)
• Hippocampal volume changes following electroconvulsive therapy: a systematic review and meta-analysis (Q89165196) (← links)
• Carbamoylated erythropoietin induces a neurotrophic gene profile in neuronal cells (Q90290199) (← links)